medigraphic.com
ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)

2011, Number 4

<< Back Next >>

Biotecnol Apl 2011; 28 (4)

Development, validation and application of a new ELISA for process control of the production of recombinant Hepatitis B surface antigen

Leyva A, Sánchez JC, López L, Font M, González T, Pérez B, Hernández N, Martínez Y, Pereira A, Rodríguez I

Language: English
References: 24
Page: 228-234
PDF size: 198.5 Kb.


ABSTRACT

The present work describes the development and validation of a sandwich-type enzyme-linked immunosorbent assay (ELISA) for quantifying the surface antigen of hepatitis B virus (HBsAg), obtained from a recombinant strain of the methylotrophic yeast Pichia pastoris. It is based on monoclonal antibody CB.Hep-1, normally employed as a ligand for the purification of HBsAg. Validation followed the guidelines of ICH Q2 and CECMED regulation No. 41 from 2007. Parameters such as linear working range, specificity, precision and accuracy were analyzed. The assay has a lower quantification limit of 11.9 ng/mL. Monoclonal antibody CB.Hep-1, used both for coating and as a conjugate during the ELISA, specifically bound recombinant HBsAg with excellent accuracy. An analysis of variance for the interference study yielded a probability, for each process control sample type/buffer combination, higher than 0.1, for a confidence level of 99%. Intra-assay variability ranged from 0.77 to 7.47%, and inter-assay variability ranged from 1.19 to 19.41%, always staying, for each sample, below 10 and 20% respectively. Recovery ranged from 98.18 to 100.31%, with a variation coefficient under 20%. The ELISA is specific for this monoclonal antibody within the range of studied concentrations, and has a linear response for antigen concentrations from 191.7 to 11.9 ng/mL. Given its precision, specificity and accuracy, this ELISA is a powerful tool for process control during the production of the recombinant vaccine against HBV.


REFERENCES

  1. Centers for Disease Control and Prevention. Achievements in public health: hepatitis B vaccination. United States, 1982-2002. MMWR Morb Mortal Wkly Rep. 2002;51(2):529-52.

  2. Burrell CJ, Mackay P, Greenaway PJ, Hofschneider PH, Murray K. Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322. Nature. 1979;279(5708):43-7.

  3. Miyanohara A, Toh-e A, Nozaki C, Hamada F, Ohtomo N, Matsubara K. Expression of hepatitis B surface antigen gene in yeast. Proc Natl Acad Sci USA. 1983;80(1):1-5.

  4. Gellissen G, Janowicz ZA, Weydemann U, Melber K, Strasser AW, Hollenberg CP. High-level expression of foreign genes in Hansenula polymorpha. Biotechnol Adv. 1992;10(2):179-89.

  5. Hsiung N, Fitts R, Wilson S, Milne A, Hamer D. Efficient production of hepatitis B surface antigen using a bovine papilloma virus-metallothionein vector. J Mol Appl Genet. 1984;2(5):497-506.

  6. Holzer GW, Mayrhofer J, Leitner J, Blum M, Webersinke G, Heuritsch S, et al. Overexpression of hepatitis B virus surface antigens including the preS1 region in a serum-free Chinese hamster ovary cell line. Protein Expr Purif. 2003;29(1):58-69.

  7. Kang CY, Bishop DH, Seo JS, Matsuura Y, Choe M. Secretion of particles of hepatitis B surface antigen from insect cells using a baculovirus vector. J Gen Virol. 1987;68(Pt 10):2607-13.

  8. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK, Arntzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA. 1996;93(11):5335-40.

  9. Muzio VL, Pentón E, Palou M, Fontirrochi G, Nazábal M, González MJ, et al, inventors; Centro de Ingeniería Genética y Biotecnología, assignee. Method for obtaining recombinant surface antigen of hepatitis B virus (HEP B) of higher immunogenic capacity and use thereof in a vaccine preparation. European Patent EP480525. 1992 Apr 15.

  10. Agraz A, Duarte CA, Costa L, Pérez L, Páez R, Pujol V, et al. Immunoaffinity purification of recombinant hepatitis B surface antigen from yeast using a monoclonal antibody. J Chromatogr A. 1994;672(1-2):25-33.

  11. Páez R, Agraz A, Herrera L. The recovery of the hepatitis B virus surface antigen (AgsHB) from a recombinant P. pastoris strain, disruption and precipitation studies. Acta Biotechnol. 1993;13:117-22.

  12. Pérez L, López S, Beldarraín A, Arenal D, Pentón E. Purification of recombinant hepatitis B surface antigen (rec-HBsAg) from P. pastoris: a process development study. In: Galindo E, Ramírez OT, editors. Advances in Bioprocess Engineering. Dordrecht: Kluwer Academic Publishers; 1994. p. 527-34.

  13. Hardy E, Martínez E, Diago D, Díaz R, González D, Herrera L. Large-scale production of recombinant hepatitis B surface antigen from Pichia pastoris. Biotechnol. 2000;77(2-3):157-67.

  14. Fernández de Cossío ME, Díaz T, Galván A, Valdéz R, González E, Ayala M, et al. Antigen recognition characteristics and comparative performance in immunoaffinity purification of two monoclonal antibodies specific for the hepatitis B virus surface antigen. J Biotechnol. 1997;56(2):69-80.

  15. Centro para el Control Estatal de la Calidad de los Medicamentos (CECMED). Regulación No. 41-2007: Validación de Métodos Analíticos. Ámbito Regulador. 2007 Mar 3;(53):1-14.

  16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of Analytical Procedures: Text and Methodology Q2(R1). ICH; 2005 Nov.

  17. Nakane PK, Kawaoi A. Peroxidase-labeled antibody. A new method of conjugation. J Histochem Cytochem. 1974;22(12):1084-91.

  18. Zor T, Selinger Z. Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal Biochem. 1996;236(2):302-8.

  19. Myers RH, Montomery DC. Response surface methodology: process and process optimization using designed experiments. 2nd ed. NewYork: John Wiley & Sons; 2002.

  20. van Roosmalen MH, de Jong JJ, Haenen W, Jacobs T, Couwenberg F, Ahlers-de Boer GJCM, et al. A new HBsAg screening assay designed for sensitive detection of HBsAg subtypes and variants. Intervirology. 2006;49:127-32.

  21. Leyva A, Franco A, González T, Sánchez JC, López I, Geada D, et al. A rapid and sensitive ELISA to quantify an HBsAg specific monoclonal antibody and a plant-derived antibody during their downstream purification process. Biologicals. 2007;35(1):19-25. 22. Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal. 2000;21(6):1249-73.

  22. Karakuş R, Aral LA, Baştürk B, Aybay C. Development of a highly sensitive ELISA for quantification of hepatitis B virus (HBV) surface antigen (HBsAg). Turk J Med Sci. 2007;37(2):87-92.

  23. Wapenaar W, Barkema HW, Vanleeuwen JA, McClure JT, O’Handley RM, Kwok OC, et al. Comparison of serological methods for the diagnosis of Neospora caninum infection in cattle. Vet Parasitol. 2007;143(2):166-73.

  24. Fuge J. FDA CONFERENCE Report: Validation Considerations When Preparing For FDA Inspections. J Validat Technol. 2005;11(3):253-6.




2020     |     www.medigraphic.com